MX2023004718A - Antigeno quimerico que comprende el dominio extracelular de pd-l1. - Google Patents
Antigeno quimerico que comprende el dominio extracelular de pd-l1.Info
- Publication number
- MX2023004718A MX2023004718A MX2023004718A MX2023004718A MX2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- extracellular domain
- metastasis
- pharmaceutical composition
- treating cancer
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 102000008096 B7-H1 Antigen Human genes 0.000 title 1
- 108010074708 B7-H1 Antigen Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Antígeno quimérico que comprende el dominio extracelular del ligando 1 del receptor proteico de muerte celular programada 1 (PD-L1) humano y que forma un multímero que tiene reducida la capacidad de unión a los receptores PD-1 y CD80 respecto a la forma nativa de PD-L1; la composición farmacéutica que comprende dicho antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable; uso de ese antígeno quimérico para la manufactura de un medicamento para el tratamiento del cáncer o sus metástasis; la invención también revela un método para el tratamiento del cáncer o sus metástasis en un individuo que lo necesita que se caracteriza porque se administra una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende dicho antígeno quimérico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000075A CU24705B1 (es) | 2020-10-22 | 2020-10-22 | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| PCT/CU2021/050008 WO2022083805A1 (es) | 2020-10-22 | 2021-09-28 | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004718A true MX2023004718A (es) | 2023-05-10 |
Family
ID=78598633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004718A MX2023004718A (es) | 2020-10-22 | 2021-09-28 | Antigeno quimerico que comprende el dominio extracelular de pd-l1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390369A1 (es) |
| EP (1) | EP4234029A1 (es) |
| JP (1) | JP7585480B2 (es) |
| KR (1) | KR20230107810A (es) |
| CN (1) | CN116783221A (es) |
| AU (1) | AU2021363436A1 (es) |
| CA (1) | CA3196460A1 (es) |
| CU (1) | CU24705B1 (es) |
| MX (1) | MX2023004718A (es) |
| WO (1) | WO2022083805A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025189420A1 (en) * | 2024-03-14 | 2025-09-18 | Topmunnity Therapeutics Taiwan Limited | Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6149921A (en) | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| PL2768524T3 (pl) * | 2011-10-17 | 2022-09-19 | Io Biotech Aps | Immunoterapia oparta na pd-l1 |
| JP6549560B2 (ja) * | 2013-05-14 | 2019-07-24 | 上海 ハイチャーム インコーポレーテッドＳｈａｎｇｈａｉ Ｈｙｃｈａｒｍ Ｉｎｃ． | 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用 |
| AU2017266905B2 (en) * | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| BR112019019251A2 (pt) | 2017-03-17 | 2020-04-28 | Vaximm Ag | cepa atenuada de salmonella |
| CU24534B1 (es) | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
-
2020
- 2020-10-22 CU CU2020000075A patent/CU24705B1/es unknown
-
2021
- 2021-09-28 JP JP2023524660A patent/JP7585480B2/ja active Active
- 2021-09-28 EP EP21806135.6A patent/EP4234029A1/en active Pending
- 2021-09-28 WO PCT/CU2021/050008 patent/WO2022083805A1/es not_active Ceased
- 2021-09-28 CA CA3196460A patent/CA3196460A1/en active Pending
- 2021-09-28 AU AU2021363436A patent/AU2021363436A1/en active Pending
- 2021-09-28 CN CN202180072039.2A patent/CN116783221A/zh active Pending
- 2021-09-28 MX MX2023004718A patent/MX2023004718A/es unknown
- 2021-09-28 KR KR1020237015994A patent/KR20230107810A/ko active Pending
- 2021-09-28 US US18/033,035 patent/US20230390369A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CU20200075A7 (es) | 2022-05-11 |
| KR20230107810A (ko) | 2023-07-18 |
| AU2021363436A9 (en) | 2024-10-10 |
| AU2021363436A1 (en) | 2023-06-01 |
| US20230390369A1 (en) | 2023-12-07 |
| CA3196460A1 (en) | 2022-04-28 |
| CN116783221A (zh) | 2023-09-19 |
| JP7585480B2 (ja) | 2024-11-18 |
| WO2022083805A1 (es) | 2022-04-28 |
| JP2023546485A (ja) | 2023-11-02 |
| EP4234029A1 (en) | 2023-08-30 |
| CU24705B1 (es) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
| KR20180004740A (ko) | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 | |
| MX2019015057A (es) | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). | |
| HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| AR109461A2 (es) | Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento | |
| CA2988604C (en) | Pharmaceutical combination and uses thereof | |
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| AR112536A1 (es) | Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
| MX2021005822A (es) | Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr. | |
| MX2023001287A (es) | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| MX2023004718A (es) | Antigeno quimerico que comprende el dominio extracelular de pd-l1. | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| Fernández-Araujo et al. | Key role of phosphodiesterase 4A (PDE4A) in autophagy triggered by yessotoxin | |
| MX2023004533A (es) | Formulaciones de anticuerpos anti-siglec-8. | |
| PE20240591A1 (es) | Anticuerpos anti-variable delta 1 de tcr multiespecificos | |
| PE20220932A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| Fernández et al. | [Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma | |
| AR118847A1 (es) | Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos |